Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
about
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific RegionThe Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled TrialCognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease.Beneficial effects of intravenous dexmedetomidine on cognitive function and cerebral injury following a carotid endarterectomy.Alzheimer's Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy OutcomeUsing baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change?Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.Focused ultrasound as a novel strategy for Alzheimer disease therapeutics.The improvement of spatial memory deficits in APP/V717I transgenic mice by chronic anti-stroke herb treatment.
P2860
Q28067006-22DAD64B-F985-4944-8A08-A907D2CD2678Q33165801-CAFACA6D-42C8-4F73-94C5-60DA53D07F8EQ35663934-38FC9013-DDB0-4D19-8E99-2029C7483A0CQ36384458-BA85118B-4C70-4D7D-89E2-CB291464347BQ36640451-6722D976-725D-4AC4-9F80-F2652E2C23B1Q36781717-100C9D21-9852-4CA7-A5CC-BAA05E128FC0Q37292848-773A5A03-2B47-48F9-87F1-07EEC3AB9E45Q38906350-1AB7ACA2-DF0E-4AB8-B4B0-DD71C47DAD0AQ48850171-D806E5FC-2FC1-4B12-A0C8-85C5E5F022DBQ50239472-71DFA46F-63C7-465F-B4F6-5D42681F9722Q50659446-2B039E86-59B5-4255-9AFB-471781FB794C
P2860
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Evaluating the cognitive effec ...... eatures on treatment response.
@ast
Evaluating the cognitive effec ...... eatures on treatment response.
@en
Evaluating the cognitive effec ...... eatures on treatment response.
@nl
type
label
Evaluating the cognitive effec ...... eatures on treatment response.
@ast
Evaluating the cognitive effec ...... eatures on treatment response.
@en
Evaluating the cognitive effec ...... eatures on treatment response.
@nl
prefLabel
Evaluating the cognitive effec ...... eatures on treatment response.
@ast
Evaluating the cognitive effec ...... eatures on treatment response.
@en
Evaluating the cognitive effec ...... eatures on treatment response.
@nl
P2093
P2860
P356
P1433
P1476
Evaluating the cognitive effec ...... eatures on treatment response.
@en
P2093
Daniel Christensen
Joan Mackell
Martin Farlow
Marwan Sabbagh
Rachelle Doody
Randi Fain
P2860
P2888
P356
10.1186/1471-2318-13-56
P577
2013-06-06T00:00:00Z
P5875
P6179
1044745778